While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...
Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year. | For ...
U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...
Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma ...
Zacks.com on MSN15d
Pfizer Rises 5.6% in a Month: How Should You Play the Stock?Pfizer’s PFE stock has risen 5.6% in the past month. This was due to the company’s encouraging guidance for 2025 issued in ...
Adjusted EPS guidance incorporates a 40-cent dilution related to the Seagen acquisition. Looking ahead, Pfizer projects a 10% to 18% operational adjusted diluted EPS growth for 2025 with ~flat to ...
Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Pfizer (PFE – Research Report) and keeping the price target at $36.00.Stay ...
While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. PFE Albert Bourla, Chairman and CEO, said, “I think we did significant transformative changes in Pfizer.” Pfizer’s CEO ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback